Comparative statistics by cancer registry

Table4: Site-wise number of cases, 5-year absolute and relative survival by sex and relative survival by age group

(Singapore, 1993-1997 cases followed-up until 2001)

Click on cancer site (ICD-10 code) for comparison

Site	ICD-10	No. of cases	Male			Female			Number of cases by age group					Relative survival by age group
			5-year survival			5-year survival			Number of cases by age group					Relative survival by age group
			No.	Abs	Rel	No.	Abs	Rel	<45	45-54	55-64	65-74	75+	<45	45-54	55-64	65-74	75+
C01-02	Tongue	120	73	24.4	28.2	47	48.9	55.8	23	17	34	20	26	30.6	54.3	34.8	56.7	28.2
C03-06	Oral cavity	135	91	31.3	37.7	44	40.9	46.3	12	16	39	36	32	92.3	44.7	30.1	47.3	21.0
C07-08	Salivary gland	87	50	61.4	66.7	37	69.9	72.5	33	17	14	14	9	84.7	77.9	67.7	51.7	20.7
C09	Tonsil	38	27	32.6	35.4	11	45.5	49.4	5	8	13	9	3	80.6	38.7	48.1	13.0	0.0
C11	Nasopharynx	1404	1046	54.1	56.9	358	64.6	67.1	547	407	281	110	59	67.1	60.7	50.6	51.2	32.7
C12-13	Hypopharynx	90	84	9.4	11.4	6			3	16	20	28	23	0.0	12.9	21.5	4.5	6.9
C15	Oesophagus	446	342	4.9	5.8	104	6.5	7.7	8	45	97	148	148	38.0	9.1	4.5	9.8	0.7
C16	Stomach	2100	1289	19.0	23.3	811	20.0	23.2	145	211	450	623	671	28.9	29.0	31.6	21.5	15.3
C17	Small intestine	80	43	25.4	30.1	37	18.9	21.3	15	12	15	24	14	26.9	42.7	28.5	19.3	13.8
C18	Colon	2501	1270	41.9	51.3	1231	41.6	49.2	196	303	551	747	704	55.4	56.0	54.6	47.8	45.6
C19-20	Rectum	1753	1006	40.3	48.2	747	46.0	53.4	162	245	433	499	414	54.0	52.4	57.0	47.3	44.5
C21	Anus	53	22	22.7	31.3	31	38.6	49.9	1	4	11	11	26	0.0	76.3	48.2	32.6	38.8
C22	Liver	1550	1204	4.6	5.4	346	3.6	4.2	157	191	363	469	370	10.9	6.9	4.3	3.7	4.1
C23-24	Gall bladder	289	132	12.8	15.3	157	11.2	13.0	20	42	58	91	78	25.2	18.8	16.6	14.3	4.3
C25	Pancreas	512	290	3.2	3.8	222	3.6	4.1	25	64	115	164	144	8.1	3.2	6.4	2.9	3.0
C30-31	Nose/Sinuses	71	49	30.5	34.9	22	63.6	69.6	11	10	22	17	11	45.8	71.5	39.6	50.3	27.3
C32	Larynx	311	284	45.5	55.2	27	66.7	76.9	10	37	88	99	77	80.9	78.2	57.0	56.9	42.7
C33-34	Lung	4253	2941	5.8	7.1	1312	6.3	7.2	195	374	918	1520	1246	9.8	13.6	10.0	5.9	3.7
C37-38	Other thoracic organs	63	42	40.3	42.5	21	52.4	53.8	31	10	16	4	2	54.9	51.0	33.9	29.4	0.0
C40-41	Bone	61	33	36.4	36.9	28	37.6	39.8	44	6	6	2	3	40.7	11.3	35.5	56.5	50.4
C43	Melanoma skin	60	28	28.6	34.1	32	40.3	44.1	19	6	6	13	16	47.6	48.6	35.6	45.1	21.2
C44	Other skin	1037	490	76.5	98.0	547	74.1	93.8	113	114	193	230	387	96.3	95.3	92.9	96.4	97.5
C45	Mesothelioma	34	26	6.9	7.3	8	12.5	13.1	4	6	11	9	4	25.2	17.2	9.5	0.0	0.0
C47+C49	Connective tissue	166	96	53.1	57.2	70	48.6	52.1	74	21	30	24	17	58.4	53.7	75.3	40.4	20.2
C48	Peritoneum	40	12	16.7	17.6	28	28.4	29.3	12	9	7	10	2	33.4	34.1	30.5	11.2	0.0
C50	Breast	3204	13	76.2	88.4	3191	72.1	76.1	936	1025	645	369	229	77.8	78.9	75.8	72.0	63.0
C51	Vulva	35				35	54.3	62.0	3	7	7	6	12	100.6	43.7	60.0	77.7	58.3
C53	Cervix	984				984	59.9	63.5	273	273	214	128	96	77.6	61.3	58.7	59.2	43.0
C54	Corpus uteri	483				483	76.4	80.6	96	140	142	75	30	87.8	86.8	79.0	68.1	65.5
C56	Ovary	718				718	61.2	63.7	270	189	116	89	54	83.6	60.5	52.0	45.9	24.8
C60	Penis	41	41	55.5	66.2				2	7	10	16	6	101.3	59.2	76.9	60.6	58.6
C61	Prostate	752	752	44.6	63.0				4	7	98	283	360	50.5	42.6	67.0	66.2	59.8
C62	Testis	75	75	85.1	86.7				57	9	7	2	0	91.9	91.3	58.9	0.0	0.0
C64	Kidney	369	253	44.1	50.2	116	48.0	51.5	58	76	87	92	56	60.8	64.5	53.4	45.1	22.3
C65	Renal pelvis	44	31	25.6	29.7	13	46.2	51.8	2	6	15	14	7	50.5	34.6	21.9	68.8	0.0
C67	Urinary bladder	496	390	53.1	65.6	106	47.0	58.2	34	52	100	147	163	77.2	81.1	82.8	57.3	47.9
C70-72	Brain & nervous system	290	163	31.7	32.6	127	28.3	28.8	171	32	36	34	17	43.8	28.8	9.0	3.7	0.0
C73	Thyroid	554	123	79.6	85.7	431	88.2	91.6	287	93	74	56	44	99.8	95.4	90.1	66.2	41.5
C74	Adrenal gland	28	14	35.7	36.3	14	42.9	43.4	20	1	3	1	3	50.1	101.9	0.0	0.0	0.0
C81	Hodgkin lymphoma	73	44	65.7	68.7	29	75.9	77.1	42	15	6	8	2	86.1	54.2	51.4	60.9	0.0
C82-85+C96	Non-Hodgkin lymphoma	790	476	37.9	42.4	314	49.5	54.0	231	122	159	144	134	54.0	64.0	46.5	39.4	25.5
C90	Multiple myeloma	159	82	20.2	22.9	77	14.1	15.7	11	29	37	42	40	45.9	49.6	20.3	1.7	3.9
C91	Lymphoid leukaemia	205	127	41.6	42.8	78	50.0	51.0	155	11	14	18	7	51.6	37.1	23.5	33.5	0.0
C92-94	Myeloid leukaemia	390	224	16.2	17.3	166	17.3	18.2	152	42	57	75	64	32.2	14.4	10.8	4.4	4.5
C95	Leukaemia unspecified	72	37	8.1	8.9	35	8.6	9.0	27	4	8	16	17	22.3	0.0	0.0	0.0	0.0

Graphs:

5-year absolute survival for male

5-year relative survival for male

5-year absolute survival for female

5-year relative survival for female

5-year relative survival by age group: -45

5-year relative survival by age group: 45-54

5-year relative survival by age group: 55-64

5-year relative survival by age group: 65-74

5-year relative survival by age group: +75

Other tables available for this registry:

- Table1:	Data quality indices - Proportion (%) of histologically verified and death certificate only cases, number and proportion of included and excluded cases by site (Singapore, 1993-1997 cases followed-up until 2001)
- Table2b:	Number and proportion of cases by vital status and median follow-up (in months) by site (Singapore, 1993-1997 cases followed-up until 2001)
- Table3:	Comparison of 1-, 3- and 5-year absolute and relative survival and 5-year age-standardized relative survival (ASRS) by site (Singapore, 1993-1997 cases followed-up until 2001)
- Table4:	Site-wise number of cases, 5-year absolute and relative survival by sex and relative survival by age group (Singapore, 1993-1997 cases followed-up until 2001)
- Table5b:	Proportion (%) of cases and 5-year absolute survival by extent of disease and site (Singapore, 1993-1997)
- Table6:	Comparison of 5-year absolute and relative survival of cases diagnosed between 1988-1992 and 1993-1997 (Singapore)
- Table7b:	Number of cases by cancer site and calendar period (Singapore Cancer Registry, 1968-1997)
- Table8:	Up-to-date 5-year relative survival estimates using cohort and period approaches by site and calendar period (Singapore, 1968-1997 cases followed-up until 1997)
- Table9:	Up-to-date 10- and 15-year relative survival estimates using cohort and period approaches by site and calendar period (Singapore, 1968-1997 cases followed-up until 1997)

Registry chapter:

Consult the chapter in Cancer survival in developping countries (Volume II)

Cancer survival in Africa, Asia, the Caribbean and Central America (SurvCan)

Comparative statistics by cancer registry

Table4: Site-wise number of cases, 5-year absolute and relative survival by sex and relative survival by age group